AU2021213469A1 - Compositions for the treatment of angiolipoma - Google Patents

Compositions for the treatment of angiolipoma Download PDF

Info

Publication number
AU2021213469A1
AU2021213469A1 AU2021213469A AU2021213469A AU2021213469A1 AU 2021213469 A1 AU2021213469 A1 AU 2021213469A1 AU 2021213469 A AU2021213469 A AU 2021213469A AU 2021213469 A AU2021213469 A AU 2021213469A AU 2021213469 A1 AU2021213469 A1 AU 2021213469A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
angiolipoma
alkyl
alkenyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021213469A
Other languages
English (en)
Inventor
Eran Blaugrund
Alon BLOOMENFELD
Racheli GUETA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raziel Therapeutics Ltd
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Publication of AU2021213469A1 publication Critical patent/AU2021213469A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AU2021213469A 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma Pending AU2021213469A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966577P 2020-01-28 2020-01-28
US62/966,577 2020-01-28
PCT/IB2021/000035 WO2021152390A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Publications (1)

Publication Number Publication Date
AU2021213469A1 true AU2021213469A1 (en) 2022-08-25

Family

ID=77078612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021213469A Pending AU2021213469A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Country Status (7)

Country Link
US (1) US20230089484A1 (https=)
EP (1) EP4096653A4 (https=)
JP (1) JP7850665B2 (https=)
CN (1) CN115335047B (https=)
AU (1) AU2021213469A1 (https=)
IL (1) IL295014A (https=)
WO (1) WO2021152390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
AU2020347539A1 (en) * 2019-09-15 2022-03-31 Raziel Therapeutics Ltd. Compositions for the treatment of solid tumors
JP2024529906A (ja) * 2021-07-28 2024-08-14 ラジエル セラピューティクス エルティーディー． 脂肪腫の疼痛を処置するための組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
KR101986272B1 (ko) * 2011-11-15 2019-06-05 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
EP3060215A4 (en) * 2013-10-21 2017-06-14 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Also Published As

Publication number Publication date
IL295014A (en) 2022-09-01
EP4096653A4 (en) 2024-02-28
EP4096653A1 (en) 2022-12-07
JP7850665B2 (ja) 2026-04-23
WO2021152390A1 (en) 2021-08-05
US20230089484A1 (en) 2023-03-23
JP2023510865A (ja) 2023-03-15
CN115335047B (zh) 2025-09-19
CN115335047A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
AU2021213469A1 (en) Compositions for the treatment of angiolipoma
US20090325906A1 (en) Methods and compositions for therapeutic treatment
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
KR20100051829A (ko) 인산화된 피론 유사체 및 방법
KR19980081621A (ko) 과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질
CA3157869A1 (en) Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
TW202432558A (zh) 一種噠嗪稠芳環化合物及其用途
WO2020047518A1 (en) Ire1 kinase inhibitors and uses thereof
WO2019104291A1 (en) Combination of granulated dried botanical extract powder for symptom relief
US20230295135A1 (en) Certain chemical compositions and methods of use thereof
US20230355584A1 (en) Compositions and methods for the treatment of lipid-related disorders
WO2022058792A1 (en) Compositions for the treatment of fat related conditions and disorders
US20240335424A1 (en) Compositions and methods for treating lipoma pain
HK40077772A (en) Compositions for the treatment of solid tumors
SG11202111877TA (en) Method for treating cough by using diaminopyrimidine compound
US20200289593A1 (en) Spirulina carotenoid complex
US20230159569A1 (en) Dual hdac6/proteasome inhibitors, and methods of use thereof
WO2025231380A1 (en) Proteolysis targeting chimeras and methods of use thereof